Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo
Koji Kishimoto, Victor M. Dong, Shohreh Issazadeh, Eugenia V. Fedoseyeva, Ana Maria Waaga, Akira Yamada, Masayuki Sho, Gilles Benichou, Hugh Auchincloss Jr., Michael J. Grusby, Samia J. Khoury, Mohamed H. Sayegh
Koji Kishimoto, Victor M. Dong, Shohreh Issazadeh, Eugenia V. Fedoseyeva, Ana Maria Waaga, Akira Yamada, Masayuki Sho, Gilles Benichou, Hugh Auchincloss Jr., Michael J. Grusby, Samia J. Khoury, Mohamed H. Sayegh
View: Text | PDF
Article

The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo

  • Text
  • PDF
Abstract

We used signal transducer and activator of transcription 4 (STAT4) and STAT6 gene knockout (–/–) mice as recipients of fully mismatched cardiac allografts to study the role of T-cell costimulatory pathways in regulating allogeneic T-helper 1 (Th1) versus Th2 responses in vivo. STAT4–/– mice have impaired Th1 responses, whereas STAT6–/– mice do not generate normal Th2 responses. Cardiac allografts from C57BL/6 mice were transplanted into normal wild-type (WT), STAT4–/–, and STAT6–/– BALB/c recipients. STAT4–/– and STAT6–/– mice rejected their grafts with the same tempo as untreated WT recipients. CD28-B7 blockade by a single injection of CTLA4Ig induced long-term engraftment and donor-specific tolerance in all three groups of recipients. CD154 blockade by a single injection of MR1 was effective in prolonging allograft survival and inducing tolerance in STAT4–/– mice but was only marginally effective in STAT6–/– recipients and WT controls. In addition, a similar protocol of MR1 was ineffective in prolonging graft survival in CD28–/– BALB/c recipients, suggesting that the lack of efficacy seen in WT and STAT6–/– mice is not due to the presence of a functional CD28-B7 pathway. Furthermore, there was a similar differential effect of CD28-B7 versus CD154-CD40 blockade in inhibiting immune responses in animals immunized with ovalbumin and complete Freund’s adjuvant. These novel data indicate that Th1 and Th2 cells are differentially regulated by CD28-B7 versus CD154-CD40 costimulation pathways in vivo and may have potential implications for the development of therapeutic strategies such as T-cell costimulatory blockade in humans.

Authors

Koji Kishimoto, Victor M. Dong, Shohreh Issazadeh, Eugenia V. Fedoseyeva, Ana Maria Waaga, Akira Yamada, Masayuki Sho, Gilles Benichou, Hugh Auchincloss Jr., Michael J. Grusby, Samia J. Khoury, Mohamed H. Sayegh

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
Frequency of cytokine-producing donor-specific T cells in recipient WT, ...
Frequency of cytokine-producing donor-specific T cells in recipient WT, STAT4–/–, and STAT6–/– BALB/c mice following allogeneic heart transplantation. Mice were transplanted with C57BL/6 allogeneic hearts. Recipient spleens were removed at the time of rejection (9–10 days after transplant). Splenocytes (1.2 × 106 cells per well) were incubated with either recipient (open bars) or donor (filled bars) irradiated splenocytes. The frequencies of IFN-γ–producing T cells (a) and IL-5–producing T cells (b) were then determined using ELISPOT assay as described in Methods. The results are expressed as the mean number of spots per well ± SE obtained from three to four mice tested individually in each group. P values of syngeneic versus alloreactive responder frequencies in each animal group are as follows. IFN-γ: P = 0.0196, 0.0132, and 0.006 in WT, STAT4–/–, and STAT6–/– recipients, respectively. IL-5: P = 0.2327, 0.0092, and 0.0942 in WT, STAT4–/–, and STAT6–/– recipients, respectively. AP = 0.002; BP = 0.0493.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts